Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Genetics of Developmental Disorders
-
1. Imprinting disorders associated with molecular changes on chromosome 11p15
- Prof. Rosanna Weksberg
-
2. Chromatin genes and disease
- Prof. Richard Gibbons
-
3. Heterochromatin, epigenetics and gene expression
- Prof. Joel C. Eissenberg
- Cardiopulmonary Disease
-
4. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
5. Molecular genetics of pulmonary arterial hypertension
- Prof. Richard C. Trembath
- Neuromuscular System Diseases
-
6. Gene therapy for the muscular dystrophies
- Prof. Jeff Chamberlain
-
7. RAS pathway and disease: neurofibromatosis and beyond
- Prof. Eric Legius
-
8. Congenital syndromes of pain and painlessness
- Prof. Geoff Woods
- Prof. James Cox
- Endocrinology and Metabolism
-
9. Changing lives: stratified medicine in monogenic diabetes
- Prof. Andrew Hattersley
-
10. Genetics of monogenic obesity 1
- Prof. Dr. Johannes Hebebrand
- Prof. Dr. Anke Hinney
-
11. Genetics of monogenic obesity 2
- Prof. Dr. Johannes Hebebrand
- Prof. Dr. Anke Hinney
- Cancer Genetics
-
13. Inherited predisposition to breast cancer
- Prof. Diana Eccles
-
14. Genetics of breast and ovarian cancer
- Prof. Jeffrey Weitzel
-
16. NF2-related Schwannomatosis and Gorlin Syndrome
- Prof. D. Gareth R. Evans
-
17. The genetic basis of kidney cancer
- Dr. W. Marston Linehan
- Oligogenic and Complex Diseases
-
18. Ciliopathies and oligogenic phenomena
- Prof. Nicholas Katsanis
- Therapy
-
19. Mismatch repair deficient cancers & Lynch syndrome
- Prof. Sir John Burn
- Archived Lectures *These may not cover the latest advances in the field
-
20. Mismatch repair deficient cancers: diagnosis, treatment and prevention
- Prof. Sir John Burn
-
21. NF2 & Gorlins
- Prof. D. Gareth R. Evans
Printable Handouts
Navigable Slide Index
- Introduction
- A MisMatch Repair (MMR) gene defect causes Lynch syndrome
- Molecular switch model
- Slippage in coding microsatellites generates predictable novel peptides
- Multitude of non-polyp precursor lesions
- Lynch syndrome represents a “genetic model”
- BRAF V600E: a point mutation
- Tests for MMR deficiency
- MSI-Plus
- The Newcastle MSI-Plus assay
- The MSI-Plus app
- MSI-Plus assay: a screening test for urothelial cancers?
- Colorectal cancer risk in Lynch Syndrome varies by gene
- PMS2 CRCs acquire dMMR later in the course of progression
- Different pathways of Lynch syndrome carcinogenesis
- Passive immunotherapy for stage IV patients
- Immune checkpoint inhibitors
- Cancer Prevention Programme
- Two approaches
- CAPP2 participating centres
- CAPP2: Planned 10y review PLUS national registry data
- Meta-analysis of 8 vascular trials using aspirin
- 2020 NICE guidelines
- Obesity in Lynch syndrome (CAPP2 secondary analysis)
- 1879 Lynch syndrome gene carriers: dose non-inferiority randomised trial
- CAPP2: Factorial design
- CAPP2 at 10 years: RS reduces non-CRC cancers
- Non-CRC LS cancers
- Microbiome changes affect bile acids
- Acknowledgements
- Summary
Topics Covered
- Mismatch repair (MMR)
- Lynch syndrome
- Microsatellite instability (MSI)
- Colorectal cancer (CRC)
- MSI-Plus assay
- CRC risk in Lynch Syndrome
- Cancer Prevention Programme
- CAPP2
- High fiber diet
- Aspirin
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Burn, J. (2023, November 30). Mismatch repair deficient cancers & Lynch syndrome [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 14, 2024, from https://doi.org/10.69645/BGDK4285.Export Citation (RIS)
Publication History
Financial Disclosures
- Our CAPP1, CAPP2 and CaPP3 trials have been supported by Bayer Pharma who provided aspirin and placebo tablets and supported packaging costs. I am named on the patents for the Newcastle MSI-Plus assay. This was first supported by a PhD studentship funded by biotechnology company QuantuMDx ltd. The company will receive a profit share if the University succeeds in commercialising the assay. I currently chair QuantuMDx and hold shares in the company.
A selection of talks on Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is John Burn.
I'm Professor of
Clinical Genetics
at Newcastle University.
I have a special interest
in hereditary cancers
and their prevention.
I'd like to talk to you today
about mismatch repair
deficiency and Lynch syndrome.
0:16
We named this syndrome
after Henry Lynch
who was a gastroenterologist
in Omaha, Nebraska.
He spent many years
popularizing the fact
that in some families,
colorectal and other
cancers seem to run
as a hereditary trait,
as a simple dominant trait.
This is a family that was
pivotal in the discovery
of the underlying cause
of this syndrome,
a family from the
North of England,
where as you can see
shaded in yellow,
multiple members of
the family developed
mostly colorectal but
also endometrial cancers.
We shared DNA from this
family with a team in Boston
who had an idea from
their work on yeast,
which proved to be correct,
that the underlying causative
gene was the MSH2 gene.
That was published in
1993 and subsequently
we realized this is actually
a very common condition.
We're now tracking
more than 8000 people
across Europe and beyond
with this condition
to look at the pattern
of the disease.
You can see that
by the age of 75
about 80 percent of people
with an MSH2 pathogenic variant
will develop cancer in
one of multiple areas,
particularly of the colon
endometrium and
urothelial tract.
This is one of four
genes from this system
which has been implicated
in the underlying cause
of Lynch Syndrome.
MSH2 pairs up with MSH6
and MLH1 with PMS2.
There's repair clamp
around mismatches
where the replication
of DNA has gone wrong
and it needs to be corrected,
and there is a physical failure
of the bases to combine
which is identified
by this system.
We now know that at
least one in 300 people
carry a pathogenic variant
in one of these four genes
with differing patterns
of cancer as a result.